Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Mikael Rinne

Neurology Boston, MA Medical Doctor

NPI 1285838185 CMS profile 1169347

450 Brookline Ave, Boston, MA 02215

Open in the dashboard

General payments

$175,200

71 records reported · program years 2020–2025

Research payments

$4,500

Paid to them · 1 record reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mikael Rinne of Boston, MA is reported in the CMS Open Payments database as having received $175,200 across 71 general payments and $4,500 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,800 12
2024 General $28,800 11
2023 General $28,800 11
2022 General $28,800 12
2022 Research $4,500 1
2021 General $28,800 12
2020 General $31,200 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mikael Rinne
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Mikael Rinne were reported at $28,800. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Mikael Rinne Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $31,200 $367 $82–$2,309 $114
2021 $28,800 $438 $104–$2,547 $132
2022 $28,800 $442 $103–$2,388 $149
2023 $28,800 $464 $119–$2,312 $160
2024 $28,800 $468 $119–$2,323 $164
2025 $28,800 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Qiagen, LLC $175,200 71 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $175,200 71 payments
Research payments came from Research payments · program years 2020–2025
  1. Novartis Pharmaceuticals Corporation $4,500 1 payment

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record